Current status and controversies in adrenal incidentalomas

Trends in Endocrinology and Metabolism

Volumn 23, Issue 12, 2012, Pages 602-609

  Kaltsas, Gregory ^a   Chrisoulidou, Alexandra ^b   Piaditis, Georgios ^c   Kassi, Eva ^a   Chrousos, George ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b Theagenio Hospital   (Greece)

^c George Genimatas Hospital   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 6 FLUORODOPA F 18; 6 FLUORODOPAMINE F 18; CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; GLUCOCORTICOID; IODOMETOMIDATE I 123; TRACER; UNCLASSIFIED DRUG;

ADRENAL CORTEX CARCINOMA; ADRENAL INCIDENTALOMA; ADRENAL METASTASIS; ADRENALECTOMY; ARTICLE; BIOCHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; CUSHING SYNDROME; DIFFERENTIAL DIAGNOSIS; ECHOGRAPHY; FOLLOW UP; HUMAN; HYDROCORTISONE RELEASE; HYPERCORTISOLISM; NEEDLE BIOPSY; PATHOGENESIS; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADRENAL CORTEX NEOPLASMS; ADRENAL GLAND NEOPLASMS; ADRENOCORTICAL ADENOMA; CUSHING SYNDROME; DEXAMETHASONE; HUMANS; HYDROCORTISONE; INCIDENTAL FINDINGS; METABOLIC SYNDROME X; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84869509292     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2012.09.001     Document Type: Article

References (77)

1. Zeiger M.A., et al. Medical and surgical evaluation and treatment of adrenal incidentalomas. J. Clin. Endocrinol. Metab. 2011, 96:2004-2015.
2. Terzolo M., et al. AME position statement on adrenal incidentaloma. Eur. J. Endocrinol. 2011, 164:851-870.
3. Young W.F. Clinical practice. The incidentally discovered adrenal mass. N. Engl. J. Med. 2007, 356:601-610.
4. Cawood T.J., et al. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink?. Eur. J. Endocrinol. 2009, 161:513-527.
5. Nieman L.K. Approach to the patient with an adrenal incidentaloma. J. Clin. Endocrinol. Metab. 2010, 95:4106-4113.
6. Barzon L., et al. Prevalence and natural history of adrenal incidentalomas. Eur. J. Endocrinol. 2003, 149:273-285.
7. Vassiliadi D.A., et al. High prevalence of subclinical hypercortisolism in patients with bilateral adrenal incidentalomas: a challenge to management. Clin. Endocrinol. (Oxf.) 2011, 74:438-444.
8. Lacroix A. ACTH-independent macronodular adrenal hyperplasia. Best Pract. Res. Clin. Endocrinol. Metab. 2009, 23:245-259.
9. Almeida M.Q., et al. Integrated genomic analysis of nodular tissue in macronodular adrenocortical hyperplasia: progression of tumorigenesis in a disorder associated with multiple benign lesions. J. Clin. Endocrinol. Metab. 2011, 96:E728-E738.
10. Reznik Y., et al. Aberrant adrenal sensitivity to multiple ligands in unilateral incidentaloma with subclinical autonomous cortisol hypersecretion: a prospective clinical study. Clin. Endocrinol. (Oxf.) 2004, 61:311-319.
11. McDermott S., et al. Radiological evaluation of adrenal incidentalomas: current methods and future prospects. Best Pract. Res. Clin. Endocrinol. Metab. 2012, 26:21-33.
12. Boland G.W. Adrenal imaging. Abdom. Imaging 2011, 36:472-482.
13. Johnson P.T., et al. Adrenal mass imaging with multidetector CT: pathologic conditions, pearls, and pitfalls. Radiographics 2009, 29:1333-1351.
14. Blake M.A., et al. Distinguishing benign from malignant adrenal masses: multi-detector row CT protocol with 10-minute delay. Radiology 2006, 238:578-585.
15. Motta-Ramirez G.A., et al. Comparison of CT findings in symptomatic and incidentally discovered pheochromocytomas. AJR Am. J. Roentgenol. 2005, 185:684-688.
16. Boland G.W. Adrenal imaging: why, when, what, and how? Part 3. The algorithmic approach to definitive characterization of the adrenal incidentaloma. AJR Am. J. Roentgenol. 2011, 196:W109-W111.
17. Elsayes K.M., et al. Magnetic resonance characterization of pheochromocytomas in the abdomen and pelvis: imaging findings in 18 surgically proven cases. J. Comput. Assist. Tomogr. 2010, 34:548-553.
18. 18F-FDG PET for the identification of adrenocortical carcinomas among indeterminate adrenal tumors at computed tomography scanning. World J. Surg. 2010, 34:1506-1510.
19. 18F-FDG PET/CT add diagnostic accuracy in incidentally identified non-secreting adrenal tumours?. Eur. J. Nucl. Med. Mol. Imaging 2008, 35:2018-2025.
20. 18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. J. Clin. Endocrinol. Metab. 2009, 94:1713-1722.
21. 123I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes. J. Clin. Endocrinol. Metab. 2008, 93:2358-2365.
22. Havekes B., et al. New imaging approaches to phaeochromocytomas and paragangliomas. Clin. Endocrinol. (Oxf.) 2010, 72:137-145.
23. Quayle F.J., et al. Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous. Surgery 2007, 142:497-502.
24. Berland L.L. The American College of Radiology strategy for managing incidental findings on abdominal computed tomography. Radiol. Clin. North Am. 2011, 49:237-243.
25. Terzolo M., et al. Management of adrenal incidentaloma. Best Pract. Res. Clin. Endocrinol. Metab. 2009, 23:233-243.
26. Grozinsky-Glasberg S., et al. Clinically silent chromaffin-cell tumors: tumor characteristics and long-term prognosis in patients with incidentally discovered pheochromocytomas. J. Endocrinol. Invest. 2010, 33:739-744.
27. Grouzmann E., et al. Diagnostic accuracy of free and total metanephrines in plasma and fractionated metanephrines in urine of patients with pheochromocytoma. Eur. J. Endocrinol. 2010, 162:951-960.
28. Boyle J.G., et al. Comparison of diagnostic accuracy of urinary free metanephrines, vanillyl mandelic Acid, and catecholamines and plasma catecholamines for diagnosis of pheochromocytoma. J. Clin. Endocrinol. Metab. 2007, 92:4602-4608.
29. Funder J.W., et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 2008, 93:3266-3281.
30. Medeau V., et al. Clinical and biochemical characteristics of normotensive patients with primary aldosteronism: a comparison with hypertensive cases. Clin. Endocrinol. (Oxf.) 2008, 69:20-28.
31. Bernini G., et al. Primary aldosteronism in normokalemic patients with adrenal incidentalomas. Eur. J. Endocrinol. 2002, 146:523-529.
32. Piaditis G.P., et al. High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas. Clin. Endocrinol. (Oxf.) 2009, 71:772-778.
33. Nieman L.K., et al. The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J. Clin. Endocrinol. Metab. 2008, 93:1526-1540.
34. Chiodini I., et al. Beneficial metabolic effects of prompt surgical treatment in patients with an adrenal incidentaloma causing biochemical hypercortisolism. J. Clin. Endocrinol. Metab. 2010, 95:2736-2745.
35. Peppa M., et al. Adrenal incidentalomas and cardiometabolic morbidity: an emerging association with serious clinical implications. J. Intern. Med. 2010, 268:555-566.
36. Zeiger M.A., et al. American Association of Clinical Endocrinologists and American Association of Endocrine Surgeons Medical Guidelines for the Management of Adrenal Incidentalomas: executive summary of recommendations. Endocr. Pract. 2009, 15:450-453.
37. Toniato A., et al. Surgical versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a prospective randomized study. Ann. Surg. 2009, 249:388-391.
38. Chiodini I. Clinical review: diagnosis and treatment of subclinical hypercortisolism. J. Clin. Endocrinol. Metab. 2011, 96:1223-1236.
39. Masserini B., et al. The limited role of midnight salivary cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal incidentaloma. Eur. J. Endocrinol. 2009, 160:87-92.
40. Mantero F., et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J. Clin. Endocrinol. Metab. 2000, 85:637-644.
41. Stewart P.M. Is subclinical Cushing's syndrome an entity or a statistical fallout from diagnostic testing? Consensus surrounding the diagnosis is required before optimal treatment can be defined. J. Clin. Endocrinol. Metab. 2010, 95:2618-2620.
42. Newell-Price J., et al. Cushing's syndrome. Lancet 2006, 367:1605-1617.
43. Tsagarakis S., et al. Endogenous subclinical hypercortisolism: diagnostic uncertainties and clinical implications. J. Endocrinol. Invest. 2006, 29:471-482.
44. Theodoraki A., et al. Outcomes in 125 individuals with adrenal incidentalomas from a single centre. a retrospective assessment of the 1mg overnight and low dose dexamethasone suppression tests. Horm. Metab. Res. 2011, 43:962-969.
45. Barzon L., et al. Risk factors and long-term follow-up of adrenal incidentalomas. J. Clin. Endocrinol. Metab. 1999, 84:520-526.
46. Eller-Vainicher C., et al. Post-surgical hypocortisolism after removal of an adrenal incidentaloma: is it predictable by an accurate endocrinological work-up before surgery?. Eur. J. Endocrinol. 2010, 162:91-99.
47. Eller-Vainicher C., et al. Accuracy of several parameters of hypothalamic-pituitary-adrenal axis activity in predicting before surgery the metabolic effects of the removal of an adrenal incidentaloma. Eur. J. Endocrinol. 2010, 163:925-935.
48. Tsagarakis S., et al. Elevated post-dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas. Clin. Endocrinol. (Oxf.) 1998, 49:165-171.
49. Morelli V., et al. Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects. Clin. Endocrinol. (Oxf.) 2010, 73:161-166.
50. Di D.G., et al. Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. Eur. J. Endocrinol. 2012, 166:669-677.
51. Chiodini I., et al. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. J. Clin. Endocrinol. Metab. 2009, 94:3207-3214.
52. Bulow B., et al. Adrenal incidentaloma - follow-up results from a Swedish prospective study. Eur. J. Endocrinol. 2006, 154:419-423.
53. Bernini G.P., et al. Long-term morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas. Br. J. Cancer 2005, 92:1104-1109.
54. Tsvetov G., et al. Adrenal incidentaloma: clinical characteristics and comparison between patients with and without extraadrenal malignancy. J. Endocrinol. Invest. 2007, 30:647-652.
55. Androulakis I.I., et al. The clinical significance of adrenal incidentalomas. Eur. J. Clin. Invest. 2011, 41:552-560.
56. Tauchmanova L., et al. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J. Clin. Endocrinol. Metab. 2002, 87:4872-4878.
57. Yener S., et al. Is there an association between non-functioning adrenal adenoma and endothelial dysfunction?. J. Endocrinol. Invest. 2011, 34:265-270.
58. Giordano R., et al. Long-term morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal incidentalomas. Eur. J. Endocrinol. 2010, 162:779-785.
59. Peppa M., et al. Insulin resistance and metabolic syndrome in patients with nonfunctioning adrenal incidentalomas: a cause-effect relationship?. Metabolism 2010, 59:1435-1441.
60. Androulakis I.I., et al. The functional status of incidentally discovered bilateral adrenal lesions. Clin. Endocrinol. (Oxf.) 2011, 10.1111/j.1365-2265.2011.04013.x.
61. Chiodini I., et al. Subclinical hypercortisolism among outpatients referred for osteoporosis. Ann. Intern. Med. 2007, 147:541-548.
62. Chiodini I., et al. Eugonadal male patients with adrenal incidentalomas and subclinical hypercortisolism have increased rate of vertebral fractures. Clin. Endocrinol. (Oxf.) 2009, 70:208-213.
63. Tauchmanova L., et al. Effects of sex steroids on bone in women with subclinical or overt endogenous hypercortisolism. Eur. J. Endocrinol. 2007, 157:359-366.
64. Toniato A., et al. Factors influencing the rising rates of adrenal surgery: analysis of a 25-year experience. Surg. Endosc. 2009, 23:503-507.
65. Bernini G., et al. Anthropometric, haemodynamic, humoral and hormonal evaluation in patients with incidental adrenocortical adenomas before and after surgery. Eur. J. Endocrinol. 2003, 148:213-219.
66. Morelli V., et al. Role of glucocorticoid receptor polymorphism in adrenal incidentalomas. Eur. J. Clin. Invest. 2010, 40:803-811.
67. Sereg M., et al. Atherosclerotic risk factors and complications in patients with non-functioning adrenal adenomas treated with or without adrenalectomy: a long-term follow-up study. Eur. J. Endocrinol. 2009, 160:647-655.
68. Terzolo M., et al. Definition of an optimal strategy to evaluate and follow-up adrenal incidentalomas: time for further research. Eur. J. Endocrinol. 2009, 161:529-532.
69. Tsuiki M., et al. Cardiovascular risks and their long-term clinical outcome in patients with subclinical Cushing's syndrome. Endocr. J. 2008, 55:737-745.
70. Mazzuco T.L., et al. Adrenal incidentalomas and subclinical Cushing's syndrome: diagnosis and treatment. Curr. Opin. Endocrinol. Diabetes Obes. 2009, 16:203-210.
71. Mitchell I.C., et al. 'Subclinical Cushing's syndrome' is not subclinical: improvement after adrenalectomy in 9 patients. Surgery 2007, 142:900-905.
72. Gumbs A.A., Gagner M. Laparoscopic adrenalectomy. Best Pract. Res. Clin. Endocrinol. Metab. 2006, 20:483-499.
73. Pantalone K.M., et al. Change in adrenal mass size as a predictor of a malignant tumor. Endocr. Pract. 2010, 16:577-587.
74. Ramacciato G., et al. Minimally invasive adrenalectomy: a multicenter comparison of transperitoneal and retroperitoneal approaches. Am. Surg. 2011, 77:409-416.
75. Terzolo M., et al. Subclinical Cushing's syndrome in adrenal incidentalomas. Endocrinol. Metab. Clin. North Am. 2005, 34:423-439.
76. Libe R., et al. Long-term follow-up study of patients with adrenal incidentalomas. Eur. J. Endocrinol. 2002, 147:489-494.
77. Mansmann G., et al. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr. Rev. 2004, 25:309-340.